J Korean Diabetes.  2025 Mar;26(1):18-21. 10.4093/jkd.2025.26.1.18.

Prevention and Management of Prediabetes

• Lee JM

• KMID: 2567086
• DOI: http://doi.org/10.4093/jkd.2025.26.1.18

Abstract

Diabetes, one of the representative chronic diseases and a key risk factor for cardiovascular disease, is continuously increasing in prevalence. The complications associated with metabolic diseases, such as hypertension and dyslipidemia are becoming significant public health concern. In general, diabetes is a progressive disease that requires active treatment upon onset, and the number of medications needed tends to increase over time. Due to these characteristics, treatment and management in the prediabetic stage are being emphasized. In addition to the increasing prevalence of diabetes, the prevalence of prediabetes in Korea is also gradually increasing to 41.1% in adults aged 30 years or older and 47.7% in adults aged 65 years or older. This trend is driven by various factors such as westernized lifestyle, rising obesity rates, and environmental factors such as age, diet, lack of exercise, stress, and medications. In this article, I introduce key points for prevention of progression to diabetes in the prediabetic stage.

Keyword

Diabetes mellitus; Prediabetic state; Prevention & control

Reference

1.Park SE., Ko SH., Kim JY., Kim K., Moon JH., Kim NH, et al. Diabetes fact sheets in Korea 2024. Diabetes Metab J. 2025. 49:24–33.

2.Pan XR., Li GW., Hu YH., Wang JX., Yang WY., An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997. 20:537–44.

3.Tuomilehto J., Lindström J., Eriksson JG., Valle TT., Hämäläinen H., Ilanne-Parikka P., Finnish Diabetes Prevention Study Group, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001. 344:1343–50.

4.Li G., Zhang P., Wang J., Gregg EW., Yang W., Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008. 371:1783–9.

5.Gong Q., Gregg EW., Wang J., An Y., Zhang P., Yang W, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011. 54:300–7.

6.Li G., Zhang P., Wang J., An Y., Gong Q., Gregg EW, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014. 2:474–80.

7.Gong Q., Zhang P., Wang J., Ma J., An Y., Chen Y., Da Qing Diabetes Prevention Study Group, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019. 7:452–61.

8.Chen Y., Zhang P., Wang J., Gong Q., An Y., Qian X, et al. Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2021. 64:1279–87.

9.Lindström J., Ilanne-Parikka P., Peltonen M., Aunola S., Eriksson JG., Hemiö K., Finnish Diabetes Prevention Study Group, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006. 368:1673–9.

10.Lindström J., Peltonen M., Eriksson JG., Ilanne-Parikka P., Aunola S., Keinänen-Kiukaanniemi S., Finnish Diabetes Prevention Study (DPS), et al. Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013. 56:284–93.

11.Uusitupa M., Peltonen M., Lindström J., Aunola S., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., Finnish Diabetes Prevention Study Group, et al. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study—secondary analysis of the randomized trial. PLoS One. 2009. 4:e5656.

12.Diabetes Prevention Program Research Group., Knowler WC., Fowler SE., Hamman RF., Christophi CA., Hoffman HJ., Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009. 374:1677–86.

13.Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015. 3:866–75.

14.Diabetes Prevention Program Research Group. Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care. 2019. 42:601–8.

15.Knowler WC., Barrett-Connor E., Fowler SE., Hamman RF., Lachin JM., Walker EA., Diabetes Prevention Program Research Group, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002. 346:393–403.

16.Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar AD., Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006. 49:289–97.

17.Chiasson JL., Josse RG., Gomis R., Hanefeld M., Karasik A., Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002. 359:2072–7.

18.Torgerson JS., Hauptman J., Boldrin MN., Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004. 27:155–61.

19.Kawamori R., Tajima N., Iwamoto Y., Kashiwagi A., Shima-moto K., Kaku K; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009. 373:1607–14.

20.Korean Diabetes Association. 2023 Clinical practice guidelines for diabetes. 8th ed.Seoul: Korean Diabetes Association;2023. p. 38–50.